What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
Kazuhiko Nakagawa focuses on Internal medicine, Lung cancer, Oncology, Surgery and Chemotherapy.
In most of his Internal medicine studies, his work intersects topics such as Gastroenterology.
His study in Lung cancer is interdisciplinary in nature, drawing from both Carboplatin, Cisplatin, Epidermal growth factor receptor, Survival rate and Hazard ratio.
His Oncology study integrates concerns from other disciplines, such as Clinical trial and Docetaxel.
The concepts of his Surgery study are interwoven with issues in Placebo, Tolerability and Cohort study.
His Chemotherapy research integrates issues from Cancer, Thoracic Oncology and Toxicity.
His most cited work include:
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial (2971 citations)
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer (2655 citations)
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer (2444 citations)
What are the main themes of his work throughout his whole career to date?
Kazuhiko Nakagawa mostly deals with Internal medicine, Oncology, Lung cancer, Cancer research and Chemotherapy.
His Internal medicine study combines topics in areas such as Gastroenterology and Surgery.
His work carried out in the field of Oncology brings together such families of science as Cancer and Docetaxel.
His Lung cancer research includes elements of Clinical endpoint, Epidermal growth factor receptor and Hazard ratio.
His study looks at the relationship between Cancer research and fields such as Cell culture, as well as how they intersect with chemical problems.
His biological study spans a wide range of topics, including Survival rate, Radiation therapy and Toxicity.
He most often published in these fields:
- Internal medicine (60.52%)
- Oncology (45.39%)
- Lung cancer (35.81%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (60.52%)
- Oncology (45.39%)
- Lung cancer (35.81%)
In recent papers he was focusing on the following fields of study:
Kazuhiko Nakagawa mainly investigates Internal medicine, Oncology, Lung cancer, Cancer research and Phases of clinical research.
Internal medicine and Gastroenterology are frequently intertwined in his study.
The various areas that Kazuhiko Nakagawa examines in his Oncology study include Carboplatin and Nivolumab.
The study incorporates disciplines such as Clinical trial and Epidermal growth factor receptor in addition to Lung cancer.
His Cancer research research includes themes of Cell, Tyrosine kinase, non-small cell lung cancer, Breast cancer and Kinase.
Kazuhiko Nakagawa works mostly in the field of Phases of clinical research, limiting it down to topics relating to Docetaxel and, in certain cases, Nedaplatin, as a part of the same area of interest.
Between 2017 and 2021, his most popular works were:
- Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. (191 citations)
- CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer (175 citations)
- Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer (133 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
His scientific interests lie mostly in Internal medicine, Oncology, Lung cancer, Chemotherapy and Hazard ratio.
Internal medicine is closely attributed to Gastroenterology in his work.
Kazuhiko Nakagawa has included themes like Carboplatin, Phases of clinical research and Epidermal growth factor receptor in his Oncology study.
His Lung cancer study which covers Survival rate that intersects with Carcinoma.
His Chemotherapy study incorporates themes from Tremelimumab, Biopsy, Durvalumab, Cohort and Immunotherapy.
While the research belongs to areas of Hazard ratio, Kazuhiko Nakagawa spends his time largely on the problem of Chemoradiotherapy, intersecting his research to questions surrounding Vinorelbine.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
